Again, here's a post in follow up to Luke Timmerman's story yesterday regarding the impending CMS vote on Dendreon's Provenge. As expected, Provenge was judged to offer clinical benefits for the indications that it was approved for by the FDA - namely as a therapy for late stage prostate cancer patients.
Not surprisingly, off-label indications will not be approved (at its $93,000 price/patient) for reimbursement. This news was expected and is good for cancer patients awaiting treatment with Provenge, and for Dendreon employees and investors.
Posted by Bruce Lehr November 17th 2010.